Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus-Reference-Cited by-同舟云学术

Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus

Published:2019-03-22 Issue:4 Volume:39 Page:501-507
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Navarro Jordi¹²³^ORCID,Santos José Ramón⁴⁵,Silva Ana⁶,Burgos Joaquin¹²,Falcó Vicenç¹²,Ribera Esteban¹²,Imaz Arkaitz⁶,Curran Adrian¹²

Affiliation:

1. Infectious Diseases Department Vall d'Hebron University Hospital Barcelona Spain

2. Vall d'Hebron Research Institute Barcelona Spain

3. Medicine Department Autonomous University of Barcelona Barcelona Spain

4. Fundació Lluita contra la Sida University Hospital Germans Trias i Pujol Badalona Spain

5. Infectious Diseases Department University Hospital Germans Trias i Pujol Badalona Spain

6. HIV and STI Unit Infectious Diseases Department Bellvitge University Hospital‐IDIBELL L'Hospitalet de Llobregrat Spain

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/phar.2227

Reference29 articles.

1. European AIDS Clinical Society (EACS).Guidelines for the clinical management and treatment of HIV‐infected adults. Available fromhttp://www.eacsociety.org/files/guidelines_8.2-english.pdf. Accessed November 2018.

2. Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients

3. Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial

4. Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness and Tolerability of Dual Therapy with Dolutegravir Plus Darunavir/cobicistat in Treatment-Experienced Patients with HIV: A 144-Week Follow-Up;Infection & Chemotherapy;2024

2. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens;Journal of Antimicrobial Chemotherapy;2023-09-19

3. GRL-142 binds to and impairs HIV-1 integrase nuclear localization signal and potently suppresses highly INSTI-resistant HIV-1 variants;Science Advances;2023-07-14

4. Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial;eClinicalMedicine;2023-06

5. Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review;Expert Review of Anti-infective Therapy;2023-04-20